Massachusetts-based Thermo Fisher Scientific Inc. has unveiled the new Orbitrap™ Astral™ mass spectrometer, describing it as ‘one of the most significant advancements’ in mass spectrometry in 15 years.
The new Astral analyser combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that ‘previously evaded detection’ and make breakthrough discoveries ‘more efficiently than ever’.
The company says researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for everything from cardiovascular disease to cancer.
Thermo Fisher showcased the Orbitrap Astral mass spectrometer last week at the American Society for Mass Spectrometry (ASMS) annual conference, from 3rd to 8th June 2023, in Houston, Texas.
... to continue reading you must be subscribed
